| Quarter (USD) | Sep 24 | Jun 24 | Mar 24 | Dec 23 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 23 | Dec 22 | Dec 21 | Dec 20 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm | 24.65 mm |
| Cash burn (monthly) | 2.69 mm | (no burn) | 3.78 mm | 3.66 mm | 2.70 mm | 3.08 mm |
| Cash used (since last report) | 10.84 mm | n/a | 15.24 mm | 14.75 mm | 10.89 mm | 12.42 mm |
| Cash remaining | 13.81 mm | n/a | 9.42 mm | 9.90 mm | 13.76 mm | 12.23 mm |
| Runway (months of cash) | 5.1 | n/a | 2.5 | 2.7 | 5.1 | 4.0 |
| 13F holders | Current |
|---|---|
| Total holders | 20 |
| Opened positions | 12 |
| Closed positions | 3 |
| Increased positions | 2 |
| Reduced positions | 4 |
| 13F shares | Current |
|---|---|
| Total value | 8.97 bn |
| Total shares | 188.39 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Flynn James E | 155.58 mm | $52.90 mm |
| OrbiMed Israel BioFund GP Limited Partnership | 17.88 mm | $6.08 mm |
| Cystic Fibrosis Foundation | 2.75 mm | $990.00 k |
| Orbimed Advisors | 1.79 mm | $1.82 bn |
| Deerfield Management | 1.79 mm | $1.82 bn |
| Nantahala Capital Management | 1.73 mm | $1.77 bn |
| TAK Takeda Pharmaceutical Company Limited | 1.48 mm | $3.65 mm |
| Ikarian Capital | 893.00 k | $910.86 mm |
| AMR Action Fund | 876.89 k | $702.00 k |
| AIGH Capital Management | 865.40 k | $882.71 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 16 Sep 24 | Oron Assaf | Common Stock | Grant | Acquire A | No | No | 0 | 25,804 | 0.00 | 25,804 |
| 16 Sep 24 | Merav Bassan | Common Stock | Grant | Acquire A | No | No | 0 | 31,749 | 0.00 | 31,749 |
| 16 Sep 24 | Solomon Jonathan Eitan | Common Stock | Grant | Acquire A | No | No | 0 | 50,556 | 0.00 | 53,056 |
| 15 Jul 24 | Flynn James E | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 5,883,000 | 0.00 | 8,938,049 |
| 15 Jul 24 | Flynn James E | Common Stock | Option exercise | Acquire M | Yes | No | 0 | 5,883,000 | 0.00 | 8,938,049 |
| 15 Jul 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | Yes | No | 0 | 5,883 | 0.00 | 47,957 |
| 15 Jul 24 | Flynn James E | Series X Non-Voting Convertible Preferred Stock Common Stock | Option exercise | Dispose M | Yes | No | 0 | 5,883 | 0.00 | 47,957 |
| 11 Jul 24 | Greig Russell | Common Stock Options - Right to Buy Common Stock | Grant | Acquire A | No | No | 0.363 | 352,000 | 127.78 k | 352,000 |
